{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:39:42Z","timestamp":1792096782790,"version":"4.4.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1093\/schbul\/sbr148","type":"journal-article","created":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T21:16:35Z","timestamp":1325193395000},"page":"306-318","source":"Crossref","is-referenced-by-count":908,"title":["Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders\u2014A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"39","author":[{"given":"Alex J.","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davy","family":"Vancampfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Sweers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud","family":"van Winkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"De Hert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,12,29]]},"reference":[{"key":"key\n\t\t\t\t20170512041244_bib1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.yco.0000228767.71473.9e","article-title":"Physical health and schizophrenia","volume":"19","author":"Mitchell","year":"2006","journal-title":"Curr Opin Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4088\/JCP.v69n0401","article-title":"Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges","volume":"69","author":"Fleischhacker","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1600-0447.2007.01095.x","article-title":"Physical illness and schizophrenia: a review of the literature","volume":"116","author":"Leucht","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"key\n\t\t\t\t20170512041244_bib4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)","volume":"24","author":"De Hert","year":"2009","journal-title":"Eur Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.schres.2007.10.005","article-title":"Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005","volume":"98","author":"Capasso","year":"2008","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170512041244_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2006.09.032","article-title":"Metabolic syndrome and risk of incidence cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies","volume":"49","author":"Gami","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170512041244_bib9","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"Mottillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170512041244_bib10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170512041244_bib11","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/ National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170512041244_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome \u2014a new world-wide definition. A consensus statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabetic Med"},{"key":"key\n\t\t\t\t20170512041244_bib13","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170512041244_bib14","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1161\/CIRCULATIONAHA.105.559633","article-title":"Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study","volume":"112","author":"Hanley","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170512041244_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0002-9149(76)90061-8","article-title":"A general cardiovascular risk profile: the Framingham Study","volume":"38","author":"Kannel","year":"1976","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170512041244_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170512041244_bib17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.v67n0408","article-title":"Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs","volume":"67","author":"Correll","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.schres.2010.05.030","article-title":"MTHFR and risk of metabolic syndrome in patients with schizophrenia","volume":"121","author":"van Winkel","year":"2010","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170512041244_bib19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/YIC.0b013e32833bc60d","article-title":"MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study","volume":"25","author":"van Winkel","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20170512041244_bib20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","article-title":"Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, and recommendations at the system and individual levels","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.psychres.2010.03.011","article-title":"Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia","volume":"177","author":"Vancampfort","year":"2010","journal-title":"Psychiatry Res"},{"key":"key\n\t\t\t\t20170512041244_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.diabet.2010.12.007","article-title":"The association of metabolic syndrome with physical activity performance in patients with schizophrenia","volume":"37","author":"Vancampfort","year":"2011","journal-title":"Diabetes Metab"},{"key":"key\n\t\t\t\t20170512041244_bib23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/oxfordjournals.schbul.a007013","article-title":"Nutritional assessment of patients with schizophrenia: a preliminary study","volume":"29","author":"Strassnig","year":"2003","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170512041244_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2010.02.1030","article-title":"Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort","volume":"119","author":"Bobes","year":"2010","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170512041244_bib25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00125-005-1689-3","article-title":"Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study","volume":"48","author":"Tillin","year":"2005","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20170512041244_bib26","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0929-6646(09)60161-3","article-title":"Prevalence of obesity and metabolic syndrome in Taiwan","volume":"105","author":"Hwang","year":"2006","journal-title":"J Formos Med Assoc"},{"key":"key\n\t\t\t\t20170512041244_bib27","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170512041244_bib28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archinte.163.4.427","article-title":"The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988\u20131994","volume":"163","author":"Park","year":"2003","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170512041244_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09540260500071798","article-title":"The metabolic syndrome and schizophrenia: a review","volume":"17","author":"Meyer","year":"2005","journal-title":"Int Rev Psychiatr"},{"key":"key\n\t\t\t\t20170512041244_bib30","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.euroneuro.2006.06.005","article-title":"Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity","volume":"16","author":"Van Gaal","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20170512041244_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2008.01317.x","article-title":"The metabolic syndrome and schizophrenia","volume":"119","author":"Meyer","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"key\n\t\t\t\t20170512041244_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0033291709990407","article-title":"Weight gain in antipsychotic-naive patients: a review and meta-analysis","volume":"40","author":"Tarricone","year":"2010","journal-title":"Psychol Med"},{"key":"key\n\t\t\t\t20170512041244_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00023210-200822070-00002","article-title":"Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal","volume":"22","author":"Alvarez-Jim\u00e9nez","year":"2008","journal-title":"CNS Drugs"},{"key":"key\n\t\t\t\t20170512041244_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170512041244_bib36","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"The PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20170512041244_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"key\n\t\t\t\t20170512041244_bib38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","article-title":"Impaired fasting glucose tolerance in first-episode, drug-na\u00efve patients with schizophrenia","volume":"160","author":"Ryan","year":"2003","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib39","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-na\u00efve schizophrenia patients","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20170512041244_bib40","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/npp.2011.94","article-title":"Endogenic and iatrogenic diabetes mellitus in drug-naive schizophrenia: the role of olanzapine and its place the psychopharmacological treatment algorithm","volume":"36","author":"Cohen","year":"2011","journal-title":"Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20170512041244_bib41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1192\/bjp.184.47.s64","article-title":"Diabetes mellitus and schizophrenia: historical perspective","volume":"184","author":"Kohen","year":"2004","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib42","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/070674370605100608","article-title":"Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report","volume":"51","author":"Cohn","year":"2006","journal-title":"Can J Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.108.052605","article-title":"Metabolic profile of antipsychotic-naive individuals with non-affective psychosis","volume":"194","author":"Fernandez-Egea","year":"2009","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1464-5491.2007.02092.x","article-title":"Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia","volume":"24","author":"Spelman","year":"2007","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t20170512041244_bib45","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4088\/JCP.08m04508","article-title":"Metabolic risk factors in drug-naive patients with first-episode psychosis","volume":"70","author":"Verma","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","article-title":"Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis","volume":"162","author":"Graham","year":"2005","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib47","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s00213-006-0384-5","article-title":"Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia","volume":"186","author":"Wu","year":"2006","journal-title":"Psychopharmacol"},{"key":"key\n\t\t\t\t20170512041244_bib48","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","article-title":"Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double blind trial of olanzapine versus haloperidol","volume":"160","author":"Lieberman","year":"2003","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.schres.2005.07.024","article-title":"Weight gain and lipid metabolic abnormalities induced by olanzapine first-episode, drug-naive patients with psychotic disorders","volume":"80","author":"Sengupta","year":"2005","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170512041244_bib50","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2006.06.021","article-title":"Olanzapine and haloperidol in first episode psychosis: two-year data","volume":"86","author":"Green","year":"2006","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170512041244_bib51","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170512041244_bib52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2008.09.028","article-title":"Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-na\u00efve population","volume":"107","author":"Perez-Iglesias","year":"2009","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170512041244_bib53","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.diabet.2008.03.003","article-title":"Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study","volume":"34","author":"Oriot","year":"2008","journal-title":"Diabetes Metab"},{"key":"key\n\t\t\t\t20170512041244_bib54","first-page":"1","article-title":"Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices","volume":"10","author":"Mitchell","year":"2011","journal-title":"Psychol Med"},{"key":"key\n\t\t\t\t20170512041244_bib55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1192\/bjp.bp.110.084665","article-title":"A systematic evaluation and comparison of the guidelines for screening and monitoring of cardiometabolic risk in people with schizophrenia","volume":"199","author":"De Hert","year":"2011","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib56","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1176\/appi.ajp.162.6.1217","article-title":"Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications","volume":"162","author":"Straker","year":"2005","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib57","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10398560701636906","article-title":"Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders","volume":"15","author":"Srinivasan","year":"2007","journal-title":"Australas Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib58","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2008.12.003","article-title":"Assessing metabolic syndrome: waist circumference versus BMI","volume":"108","author":"Szarek","year":"2009","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170512041244_bib59","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2008.01.028","article-title":"Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review","volume":"101","author":"De Hert","year":"2008","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170512041244_bib60","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-244X-9-80","article-title":"Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration","volume":"9","author":"Shi","year":"2009","journal-title":"BMC Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/13651500310004830","article-title":"Physical examination performed by psychiatrists","volume":"8","author":"Hodgson","year":"2004","journal-title":"Int J Psychiatr Clin Pract"},{"key":"key\n\t\t\t\t20170512041244_bib62","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","author":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinology, North American Association for the Study of Obesity","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170512041244_bib63","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1179\/108331909X12540993898053","article-title":"Cardiometabolic effects of physical activity interventions for people with schizophrenia","volume":"14","author":"Vancampfort","year":"2009","journal-title":"Phys Ther Rev"},{"issue":"12","key":"key\n\t\t\t\t20170512041244_bib64","first-page":"CD006629","article-title":"Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems","author":"Mukundan","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170512041244_bib65","article-title":"Antipsychotic medications metabolic, cardiovascular and cardiac risks [published online ahead of print October 18, 2011]","author":"De Hert","journal-title":"Nat Rev Endocrinol"},{"key":"key\n\t\t\t\t20170512041244_bib66","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am J Psychiatry"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/39\/2\/306\/16975330\/sbr148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T16:53:18Z","timestamp":1640278398000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-lookup\/doi\/10.1093\/schbul\/sbr148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,29]]},"references-count":66,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,12,29]]},"published-print":{"date-parts":[[2013,3]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbr148","relation":{},"ISSN":["1745-1701","0586-7614"],"issn-type":[{"value":"1745-1701","type":"electronic"},{"value":"0586-7614","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12,29]]}}}